OKYO Pharma Limited

OKYO Pharma Limited (LSE:OKYO, OCTQB:EMMLF) is a biopharmaceutical company developing next-generation therapeutics to improve the lives of patients with inflammatory eye diseases and ocular pain. Their goal is to develop first in class drug candidates that prevent the disease instead of controlling it, and they achieve this through their collaboration with pioneer scientists in the field.